This week the FDA announced approval of a generic version of the abortion drug mifepristone. The manufacturer of this generic drug openly states that their drug is designed to “terminate a pregnancy” and that their mission is to “normalize abortion.”
Over the past several years, the FDA has steadily weakened critical safety protocols for mifepristone — such as requiring in-person medical screening, ultrasounds, and follow-up visits. These safeguards once existed to protect women from the well-documented dangers of chemical abortion.
Chemical abortion drugs have a complication rate four times higher than surgical abortions. They can cause severe bleeding, intense pain, infection, and even emergency surgery. Without doctor supervision, these risks often go unnoticed until it’s too late, endangering women’s health. Meanwhile, the widespread use of these drugs continues to take the lives of countless preborn children.
FDA commissioner Marty Makary previously announced that the FDA is investigating the safety of mifepristone. HHS Secretary Robert F. Kennedy Jr. further noted that the Biden Administration “twisted the data” to make the abortion pill appear safer than it truly is.
In response, Heather Weininger, Executive Director of Wisconsin Right to Life shared, “We urge the FDA to, at bare minimum, reinstate the reasonable safety restrictions that existed during President Trump’s first term for mifepristone and its generic counterpart. Whether brand-name or generic, these abortion drugs — without proper medical oversight — will harm women. Women deserve real healthcare, real compassion, and real support — not a pill that ends one life and endangers another.”
